Mosaic ImmunoEngineering Reports $26 Cash, Reiterates Going Concern
CPMV is trading near its 52-week low of $0.054 (13% above the low).
Summary
Mosaic ImmunoEngineering's Q2 2026 10-Q shows cash of only $26 and a going concern warning, with no revenue and no committed financing.
Key Events · Earnings and Guidance · CPMV
-
Cash Drops to $26
Cash and cash equivalents fell to $26 as of June 30, 2026, from $3,622 at December 31, 2025, leaving the company with essentially no liquidity.
-
Going Concern Warning Reiterated
Management states that cash on hand will not satisfy operational and capital requirements through twelve months from the filing date, and there are no current arrangements for additional financing.
-
Liabilities Continue to Mount
Total current liabilities increased to $6.33 million, including $4.49 million in accrued compensation and $1.50 million in convertible notes, net.
-
Net Loss Remains Steady
Net loss for the six months ended June 30, 2026 was $352,847, essentially flat compared to $353,348 in the prior year period.
Analysis · CPMV · Life Sciences
The company's cash position has deteriorated to just $26, down from $3,622 at year-end, and management confirms that current funds will not cover operations for the next twelve months. With no revenue and no committed financing, the company faces imminent insolvency unless it raises capital quickly. The going concern warning is now more acute than in the prior quarter.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.4% of the 1170 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CPMV was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $441.8K. The 52-week trading range was $0.05 to $1.13. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.